APA (7th ed.) Citation

RJ, M., T, P., M, B., B, E., MT, B., AY, S., . . . TK, C. (2022). Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial. The Lancet. Oncology, 23(7), 888. https://doi.org/10.1016/S1470-2045(22)00290-X

Chicago Style (17th ed.) Citation

RJ, Motzer, et al. "Nivolumab Plus Cabozantinib Versus Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma (CheckMate 9ER): Long-term Follow-up Results from an Open-label, Randomised, Phase 3 Trial." The Lancet. Oncology 23, no. 7 (2022): 888. https://doi.org/10.1016/S1470-2045(22)00290-X.

MLA (9th ed.) Citation

RJ, Motzer, et al. "Nivolumab Plus Cabozantinib Versus Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma (CheckMate 9ER): Long-term Follow-up Results from an Open-label, Randomised, Phase 3 Trial." The Lancet. Oncology, vol. 23, no. 7, 2022, p. 888, https://doi.org/10.1016/S1470-2045(22)00290-X.